Mexidol 50mg / 5ml 5's ml solution for injection in ampoules intravenously and intramuscularly.
- $24.10
The instruction for medical use
of MEKSIDOL® medicine
the Trade name
of Meksidol®
the International unlicensed name
Is not present
the Dosage form
Solution for intravenous and intramuscular administration of 50 mg/ml on 2 ml or 5 ml
Structure
of 1 ml of solution contains
active agent - ethylmethylhydroxypyridine succinate of 50 mg,
excipients: sodium metabisulphite, water for injections
the Description
Transparent colourless or slightly yellowish liquid
Pharmacotherapeutic group
Other drugs for treatment of diseases of nervous system.
The code of automatic telephone exchange N07XX
the Pharmacological
Pharmacokinetics At properties intramuscular introduction drug is defined in blood plasma for 4 hours after introduction. Time of achievement of the maximum concentration is 0.45-0.50 hours. The maximum concentration at doses of 400-500 mg makes 3.5-4.0 mkg/ml. Мексидол® quickly passes from the blood course into bodies and fabrics and it eliminirutsya quickly from an organism. Time of deduction (MRT) of drug in an organism is 0.7-1.3 hours. Drug is removed from an organism with urine generally in a glyukuronokonjyugirovanny form and in insignificant quantities in an invariable look.
The pharmacodynamics
of Meksidol® renders anti-hypoxemic, membranoprotektorny, nootropic, anticonvulsant, anxiolytic action, increases resistance of an organism to a stress. Мексидол® increases resistance of an organism to influence of the major disturbing factors, to kislorodzavisimy morbid conditions (shock, a hypoxia and ischemia, disturbance of cerebral circulation, intoxication alcohol and antipsychotic drugs (neuroleptics).
Мексидол® improves brain metabolism and blood supply of a brain, improves microcirculation and rheological properties of blood, reduces aggregation of thrombocytes. Stabilizes membrane structures of blood cells (erythrocytes and thrombocytes) at hemolysis. Has hypolipidemic effect, reduces the level of the general cholesterol and lipoproteids of the low density (LDL).
Reduces an enzymatic toxaemia and endogenous intoxication in acute pancreatitis.
The mechanism of action Meksidol® is caused by its antigipoksantny, antioxidant and membranoprotektorny action. It inhibits processes of peroxide oxidation of lipids, increases activity of a superoksidoksidaza, the lipid protein raises a ratio, reduces viscosity of a membrane, increases its fluidity. Modulates activity of membrane-bound enzymes (kaltsiynezavisimy phosphodiesterase, adenylatecyclase, acetylcholinesterase), receptor complexes (benzodiazepine, piperidic acid (GAMK), atsetilkholinovy) that enhances their ability of linking with ligands, helps preservation of the structurally functional organization of biomembranes, transport of neurotransmitters and improvement of synoptic transfer. Мексидол® increases dopamine content in a brain. Causes strengthening of compensatory activity of aerobic glycolysis and decrease in extent of oppression of oxidizing processes in a tricarbonic acid cycle in the conditions of a hypoxia, with increase in contents adenosine triphosphate (ATP), creatine phosphate and activation of the power synthesizing functions of mitochondrions, stabilization of cellular membranes.
Indications
- acute disorders of cerebral circulation
- distsirkulyatorny encephalopathy
- vegeto-vascular dystonia
- slight cognitive disorders of atherosclerotic genesis
- anxiety disorders at neurotic and neurosis-like states
- stopping of an abstinence syndrome in alcoholism with prevalence of neurosis-like and vegetovascular disorders
- acute intoxication antipsychotic means
- acute pyoinflammatory processes of an abdominal cavity (acute necrotic pancreatitis, peritonitis) as a part of complex therapy.
The route of administration and doses
appoint the Drug Meksidol® intramusculary or intravenously (struyno or by drop infusion). At an infusional method of administration drug should be dissolved in normal saline solution of sodium of chloride. Struyno the drug is administered slowly within 5-7 minutes, by drop infusion – with a speed of 40-60 thaws a minute. The maximum daily dose should not exceed 1200 mg.
In acute disorders of cerebral circulation drug is used in complex therapy in the first 10-14 days – intravenously by drop infusion on 200-500 mg 2-4 times a day, then intramusculary on 200-250 mg 2-3 times a day within 2 weeks.
In distsirkulyatorny encephalopathy in a decompensation phase it is intravenously struyno necessary to appoint drug or by drop infusion in a dose of 200-500 mg 1-2 times a day for 14 days. Then the drug is administered intramusculary on 100-250 mg a day for the next 2 weeks.
For course prevention of distsirkulyatorny encephalopathy the drug is administered intramusculary in a dose of 200-250 mg by 2 times a day for 10-14 days.
At easy cognitive disturbances at patients of advanced age and in anxiety disorders drug is used intramusculary in a daily dose of 100-300 mg a day for 14-30 days.
In an abstinence alcoholic syndrome the drug is administered in a dose 200-500 mg intravenously by drop infusion or intramusculary by 2-3 times a day within 5-7 days.
In acute intoxication antipsychotic means the drug is administered intravenously in a dose of 50-300 mg a day for 7-14 days.
At acute pyoinflammatory processes of an abdominal cavity (acute necrotic pancreatitis, peritonitis), drug is appointed in the first day, both in preoperative, and in the postoperative period. The entered doses depend on a form and disease severity, prevalence of process, options of a clinical course. Drug withdrawal has to be made gradually only after positive therapeutic effect.
In acute edematous (interstitial) pancreatitis drug is appointed on 200-500 mg by 3 times a day, intravenously by drop infusion (in isotonic solution of sodium of chloride) and intramusculary. Light severity of necrotic pancreatitis – on 100-200 mg 3 times a day intravenously by drop infusion (in isotonic solution of sodium of chloride) and intramusculary. Moderate severity – on 200 mg 3 times a day, intravenously by drop infusion (in isotonic solution of sodium of chloride). A heavy course – in pulse dosage of 800 mg in the first day, at the double mode of introduction, further on 200-500 mg 2 times a day with gradual decrease in a daily dose. Extremely heavy course – in an initial dosage of 800 mg a day before permanent stopping of manifestations of pankreatogenny shock, on stabilization of a state on 300-500 mg 2 times a day intravenously by drop infusion (in isotonic solution of sodium of chloride) with gradual decrease in a daily dosage.
Side effects
- nausea and dryness in a mouth, metal smack in a mouth
- drowsiness
- allergic reactions
- an unpleasant smell, irritation in a throat and discomfort in
the Contraindication thorax
- the increased individual sensitivity to drug
- acute disorders of function of a liver and kidneys
- children's and teenage age up to 18 years
- pregnancy, the lactation period
Medicinal interactions
Strengthens effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), protivoparkinsonichesky means (levodopa), nitrates. Reduces toxic effects of alcohol.
Special instructions
In some cases, especially at predisposed patients with bronchial asthma at hypersensitivity to sulfites, development of heavy reactions of hypersensitivity is possible.
The feature of influence of drug on ability to run motor transport and potentially dangerous mechanisms
Should be careful at control of motor transport and potentially dangerous mechanisms.
Overdose
Symptoms: strengthening of side effects.
Treatment: drug is temporarily cancelled. Symptomatic treatment.
Form of release and packing
Solution of 50 mg/ml in ampoules on 2 ml or 5 ml, colourless or light-protective glass with a point of a break of blue color or with a point of a break of white color and three marking rings (upper – yellow, average – white, lower – red). On 5 ampoules in blister strip packaging from a film aluminum foil, polyvinylchloride without covering. On 1 (for ampoules on 5 ml) or 2 (for ampoules on 2 ml) blister strip packagings together with the instruction for medical use put in a pack from cardboard.
To Store storage conditions in the dry, protected from light place, at a temperature not above 25ºС.
To store out of children's reach!
3 years
not to apply a period of storage after the term specified on packing.
Prescription status
According to the prescription
Federal State Unitary Enterprise Armavir Biofactory Producer according to the license of LLC NPK Pharmasoft
the Address: Russia, 352212, Krasnodar Krai, New Kuban district, item. Progress, Mechnikov St., 11
the Organization accepting claims from consumers on quality of products (goods)
of LLC NPK Pharmasoft
Russia, 115280, Moscow, Avtozavodskaya St., 22.
Ph./fax: (495)-626-47-48
E-mail:
To develop pharmasoft @pharmasoft.ru
of MEKSIDOL® medicine
the Trade name
of Meksidol®
the International unlicensed name
Is not present
the Dosage form
Solution for intravenous and intramuscular administration of 50 mg/ml on 2 ml or 5 ml
Structure
of 1 ml of solution contains
active agent - ethylmethylhydroxypyridine succinate of 50 mg,
excipients: sodium metabisulphite, water for injections
the Description
Transparent colourless or slightly yellowish liquid
Pharmacotherapeutic group
Other drugs for treatment of diseases of nervous system.
The code of automatic telephone exchange N07XX
the Pharmacological
Pharmacokinetics At properties intramuscular introduction drug is defined in blood plasma for 4 hours after introduction. Time of achievement of the maximum concentration is 0.45-0.50 hours. The maximum concentration at doses of 400-500 mg makes 3.5-4.0 mkg/ml. Мексидол® quickly passes from the blood course into bodies and fabrics and it eliminirutsya quickly from an organism. Time of deduction (MRT) of drug in an organism is 0.7-1.3 hours. Drug is removed from an organism with urine generally in a glyukuronokonjyugirovanny form and in insignificant quantities in an invariable look.
The pharmacodynamics
of Meksidol® renders anti-hypoxemic, membranoprotektorny, nootropic, anticonvulsant, anxiolytic action, increases resistance of an organism to a stress. Мексидол® increases resistance of an organism to influence of the major disturbing factors, to kislorodzavisimy morbid conditions (shock, a hypoxia and ischemia, disturbance of cerebral circulation, intoxication alcohol and antipsychotic drugs (neuroleptics).
Мексидол® improves brain metabolism and blood supply of a brain, improves microcirculation and rheological properties of blood, reduces aggregation of thrombocytes. Stabilizes membrane structures of blood cells (erythrocytes and thrombocytes) at hemolysis. Has hypolipidemic effect, reduces the level of the general cholesterol and lipoproteids of the low density (LDL).
Reduces an enzymatic toxaemia and endogenous intoxication in acute pancreatitis.
The mechanism of action Meksidol® is caused by its antigipoksantny, antioxidant and membranoprotektorny action. It inhibits processes of peroxide oxidation of lipids, increases activity of a superoksidoksidaza, the lipid protein raises a ratio, reduces viscosity of a membrane, increases its fluidity. Modulates activity of membrane-bound enzymes (kaltsiynezavisimy phosphodiesterase, adenylatecyclase, acetylcholinesterase), receptor complexes (benzodiazepine, piperidic acid (GAMK), atsetilkholinovy) that enhances their ability of linking with ligands, helps preservation of the structurally functional organization of biomembranes, transport of neurotransmitters and improvement of synoptic transfer. Мексидол® increases dopamine content in a brain. Causes strengthening of compensatory activity of aerobic glycolysis and decrease in extent of oppression of oxidizing processes in a tricarbonic acid cycle in the conditions of a hypoxia, with increase in contents adenosine triphosphate (ATP), creatine phosphate and activation of the power synthesizing functions of mitochondrions, stabilization of cellular membranes.
Indications
- acute disorders of cerebral circulation
- distsirkulyatorny encephalopathy
- vegeto-vascular dystonia
- slight cognitive disorders of atherosclerotic genesis
- anxiety disorders at neurotic and neurosis-like states
- stopping of an abstinence syndrome in alcoholism with prevalence of neurosis-like and vegetovascular disorders
- acute intoxication antipsychotic means
- acute pyoinflammatory processes of an abdominal cavity (acute necrotic pancreatitis, peritonitis) as a part of complex therapy.
The route of administration and doses
appoint the Drug Meksidol® intramusculary or intravenously (struyno or by drop infusion). At an infusional method of administration drug should be dissolved in normal saline solution of sodium of chloride. Struyno the drug is administered slowly within 5-7 minutes, by drop infusion – with a speed of 40-60 thaws a minute. The maximum daily dose should not exceed 1200 mg.
In acute disorders of cerebral circulation drug is used in complex therapy in the first 10-14 days – intravenously by drop infusion on 200-500 mg 2-4 times a day, then intramusculary on 200-250 mg 2-3 times a day within 2 weeks.
In distsirkulyatorny encephalopathy in a decompensation phase it is intravenously struyno necessary to appoint drug or by drop infusion in a dose of 200-500 mg 1-2 times a day for 14 days. Then the drug is administered intramusculary on 100-250 mg a day for the next 2 weeks.
For course prevention of distsirkulyatorny encephalopathy the drug is administered intramusculary in a dose of 200-250 mg by 2 times a day for 10-14 days.
At easy cognitive disturbances at patients of advanced age and in anxiety disorders drug is used intramusculary in a daily dose of 100-300 mg a day for 14-30 days.
In an abstinence alcoholic syndrome the drug is administered in a dose 200-500 mg intravenously by drop infusion or intramusculary by 2-3 times a day within 5-7 days.
In acute intoxication antipsychotic means the drug is administered intravenously in a dose of 50-300 mg a day for 7-14 days.
At acute pyoinflammatory processes of an abdominal cavity (acute necrotic pancreatitis, peritonitis), drug is appointed in the first day, both in preoperative, and in the postoperative period. The entered doses depend on a form and disease severity, prevalence of process, options of a clinical course. Drug withdrawal has to be made gradually only after positive therapeutic effect.
In acute edematous (interstitial) pancreatitis drug is appointed on 200-500 mg by 3 times a day, intravenously by drop infusion (in isotonic solution of sodium of chloride) and intramusculary. Light severity of necrotic pancreatitis – on 100-200 mg 3 times a day intravenously by drop infusion (in isotonic solution of sodium of chloride) and intramusculary. Moderate severity – on 200 mg 3 times a day, intravenously by drop infusion (in isotonic solution of sodium of chloride). A heavy course – in pulse dosage of 800 mg in the first day, at the double mode of introduction, further on 200-500 mg 2 times a day with gradual decrease in a daily dose. Extremely heavy course – in an initial dosage of 800 mg a day before permanent stopping of manifestations of pankreatogenny shock, on stabilization of a state on 300-500 mg 2 times a day intravenously by drop infusion (in isotonic solution of sodium of chloride) with gradual decrease in a daily dosage.
Side effects
- nausea and dryness in a mouth, metal smack in a mouth
- drowsiness
- allergic reactions
- an unpleasant smell, irritation in a throat and discomfort in
the Contraindication thorax
- the increased individual sensitivity to drug
- acute disorders of function of a liver and kidneys
- children's and teenage age up to 18 years
- pregnancy, the lactation period
Medicinal interactions
Strengthens effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), protivoparkinsonichesky means (levodopa), nitrates. Reduces toxic effects of alcohol.
Special instructions
In some cases, especially at predisposed patients with bronchial asthma at hypersensitivity to sulfites, development of heavy reactions of hypersensitivity is possible.
The feature of influence of drug on ability to run motor transport and potentially dangerous mechanisms
Should be careful at control of motor transport and potentially dangerous mechanisms.
Overdose
Symptoms: strengthening of side effects.
Treatment: drug is temporarily cancelled. Symptomatic treatment.
Form of release and packing
Solution of 50 mg/ml in ampoules on 2 ml or 5 ml, colourless or light-protective glass with a point of a break of blue color or with a point of a break of white color and three marking rings (upper – yellow, average – white, lower – red). On 5 ampoules in blister strip packaging from a film aluminum foil, polyvinylchloride without covering. On 1 (for ampoules on 5 ml) or 2 (for ampoules on 2 ml) blister strip packagings together with the instruction for medical use put in a pack from cardboard.
To Store storage conditions in the dry, protected from light place, at a temperature not above 25ºС.
To store out of children's reach!
3 years
not to apply a period of storage after the term specified on packing.
Prescription status
According to the prescription
Federal State Unitary Enterprise Armavir Biofactory Producer according to the license of LLC NPK Pharmasoft
the Address: Russia, 352212, Krasnodar Krai, New Kuban district, item. Progress, Mechnikov St., 11
the Organization accepting claims from consumers on quality of products (goods)
of LLC NPK Pharmasoft
Russia, 115280, Moscow, Avtozavodskaya St., 22.
Ph./fax: (495)-626-47-48
E-mail:
To develop pharmasoft @pharmasoft.ru
Related Products
Ellara MC OOO (Russia)
MEXIDOL® 50 mg / ml, 2ml 10s solution intravenously. and intramuscularly. introduction in vials
$24.90